Personalis, Inc. stock is down -3.27% since 30 days ago. The next earnings date is May 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 4 February’s closed higher than January.
Personalis, Inc. operates as a cancer genomics company worldwide. It provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!